Autem Therapeutics

Autem Therapeutics is a biotechnology company of undisclosed location that develops non-invasive oncology treatments utilizing low-level, amplitude-modulated electromagnetic frequencies to target cancer cell metabolism. The organization's primary technology, the AutEMsys therapy, is designed to reverse the Warburg Effect by disrupting cell division in proliferating cancer cells and starving non-dividing ones of energy. Simultaneously, the treatment aims to shrink tumors and improve overall patient survival rates while boosting the baseline energy metabolism of surrounding healthy cells. Clinical studies for the therapeutic system have involved over 200 early and advanced-stage cancer patients across more than 1,725 documented therapy exposures. Because the hardware requires no refrigeration or complex medical infrastructure, it maintains an operational capacity to treat up to 40 patients per month in remote settings. The founding year and the identities of the original founders of Autem Therapeutics remain publicly undisclosed.